Genome Editing Stocks List

Recent Signals

Date Stock Signal Type
2021-04-22 ABEO Crossed Above 20 DMA Bullish
2021-04-22 ABEO MACD Bullish Signal Line Cross Bullish
2021-04-22 ABEO Non-ADX 1,2,3,4 Bearish Bearish Swing Setup
2021-04-22 ABEO Pocket Pivot Bullish Swing Setup
2021-04-22 CRSP 50 DMA Resistance Bearish
2021-04-22 CRSP Pocket Pivot Bullish Swing Setup
2021-04-22 CRSP Non-ADX 1,2,3,4 Bearish Bearish Swing Setup
2021-04-22 CRSP Bollinger Band Squeeze Range Contraction
2021-04-22 DTIL 200 DMA Support Bullish
2021-04-22 DTIL 20 DMA Resistance Bearish
2021-04-22 EDIT Calm After Storm Range Contraction
2021-04-22 EDIT Lower Bollinger Band Walk Weakness
2021-04-22 NTLA Crossed Above 20 DMA Bullish

Recent News for Genome Editing Stocks

Date Stock Title
Apr 23 CRSP 2 Unstoppable Cathie Wood Stocks That Could Make You Rich
Apr 23 CRSP Crispr Therapeutics: Pipeline Catalyst Triggering Upside
Apr 21 CRSP Biotech Stock Roundup: BMYs Opdivo Gets FDA Nod for Gastric Cancer & Other Updates
Apr 21 ABEO 3 Penny Stocks That Wall Street Wants You To Buy Now
Apr 21 CRSP Crispr’s recent pullback is a buying opportunity says Jefferies after Vertex deal
Apr 21 CRSP Vertex (VRTX) Ups Investment in CRISPR Gene Therapy Partnership
Apr 21 CRSP Intuitive Surgical upgraded after earnings beat; Oppenheimer sizes up new Vertex – CRISPR deal, and more in today’s analyst action
Apr 21 CRSP CRISPR Therapeutics Is Upgraded After $900 Million Deal
Apr 20 CRSP Vertex Pharmaceuticals Raises Bet on CRISPR Therapeutics
Apr 20 CRSP Mid-Afternoon Market Update: Dow Tumbles 370 Points; Kansas City Southern Shares Spike Higher
Apr 20 CRSP Vertex bets on CRISPR for beta-thalassemia as Bluebird bio stumbles in Europe
Apr 20 CRSP Vertex Is Buying Majority Rights to Gene-Editing Therapy From CRISPR Therapeutics
Apr 20 CRSP Why Crispr, KalVista And Syndax Are Moving Today
Apr 20 CRSP Vertex and CRISPR amend CTX001 development agreement
Apr 20 ABEO Abeona Therapeutics Announces Presentation on New Preclinical Data Supporting the Potential of Cre-Mediated Dual AAV Vector Technology to Enable Delivery of Large Genes Targeted for Treatment of Stargardt Disease at ARVO 2021 Annual Meeting
Apr 20 CRSP Vertex Pharmaceuticals and CRISPR Therapeutics Amend Collaboration for Development, Manufacturing and Commercialization of CTX001™ in Sickle Cell Disease and Beta Thalassemia
Apr 19 CRSP CRISPR Therapeutics: A Speculative Play On The Future Of Medicine
Apr 19 ABEO Abeona Therapeutics Appoints Two Industry Leaders as New Independent Members to Its Board of Directors
Apr 19 EDIT Did You Miss Editas Medicine's (NASDAQ:EDIT) 44% Share Price Gain?
Apr 16 CRSP CRISPR Stocks: The Big Analyst Call Destroying CRSP, NTLA, EDIT Stocks Today
Related Industries: Biotechnology

Genome editing, or genome engineering, is a type of genetic engineering in which DNA is inserted, deleted, modified or replaced in the genome of a living organism. Unlike early genetic engineering techniques that randomly inserts genetic material into a host genome, genome editing targets the insertions to site specific locations.
In 2018, the common methods for such editing use engineered nucleases, or "molecular scissors". These nucleases create site-specific double-strand breaks (DSBs) at desired locations in the genome. The induced double-strand breaks are repaired through nonhomologous end-joining (NHEJ) or homologous recombination (HR), resulting in targeted mutations ('edits').
As of 2015 four families of engineered nucleases were used: meganucleases, zinc finger nucleases (ZFNs), transcription activator-like effector-based nucleases (TALEN), and the clustered regularly interspaced short palindromic repeats (CRISPR/Cas9) system. Nine genome editors were available as of 2017.Genome editing with engineered nucleases, i.e. all three major classes of these enzymes—zinc finger nucleases (ZFNs), transcription activator-like effector nucleases (TALENs) and engineered meganucleases—were selected by Nature Methods as the 2011 Method of the Year. The CRISPR-Cas system was selected by Science as 2015 Breakthrough of the Year.

More about Genome Editing
Browse All Tags